Atlas Trials

Sintilimab in FH-deficient Renal Cell Carcinoma

Clinical trial NCT04146831 · UNKNOWN

Trial details

NCT number
NCT04146831
Sponsor
West China Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell CarcinomaFH-deficientSintilimab
Start date
2020-06-01
Primary completion
2022-06-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.